Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis

Ting Wei Wang, Ming Sheng Hsu, Yi Hui Lin, Hwa Yen Chiu, Heng Sheng Chao, Chien Yi Liao, Chia Feng Lu, Yu Te Wu, Jing Wen Huang*, Yuh Min Chen*

*此作品的通信作者

研究成果: Review article同行評審

2 引文 斯高帕斯(Scopus)

摘要

In the context of non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), this research evaluated the prognostic value of CT-based radiomics. A comprehensive systematic review and meta-analysis of studies up to April 2023, which included 3111 patients, was conducted. We utilized the Quality in Prognosis Studies (QUIPS) tool and radiomics quality scoring (RQS) system to assess the quality of the included studies. Our analysis revealed a pooled hazard ratio for progression-free survival of 2.80 (95% confidence interval: 1.87–4.19), suggesting that patients with certain radiomics features had a significantly higher risk of disease progression. Additionally, we calculated the pooled Harrell’s concordance index and area under the curve (AUC) values of 0.71 and 0.73, respectively, indicating good predictive performance of radiomics. Despite these promising results, further studies with consistent and robust protocols are needed to confirm the prognostic role of radiomics in NSCLC.

原文English
文章編號3542
期刊Cancers
15
發行號14
DOIs
出版狀態Published - 7月 2023

指紋

深入研究「Application of Radiomics in Prognosing Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis」主題。共同形成了獨特的指紋。

引用此